Fulminant hepatitis B following rituximab therapy in a patient with evans syndrome and large B-cell lymphoma [5]

American Journal of Hematology

Volumn 81, Issue 4, 2006, Pages 302-

  Özgönenel, Bülent ^a   Moonka, Dilip ^b   Savaşan, Süreyya ^a  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANTIVIRUS AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; RITUXIMAB; VINCRISTINE;

ADULT; AUTOIMMUNE HEMOLYTIC ANEMIA; B CELL LYMPHOMA; CASE REPORT; DISEASE COURSE; HEPATITIS B; HUMAN; IMMUNOTHERAPY; LARGE CELL LYMPHOMA; LETTER; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; VIRUS LOAD; VIRUS REACTIVATION;

ADULT; ANEMIA, HEMOLYTIC, CONGENITAL; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FATAL OUTCOME; HEPATITIS B; HUMANS; LIVER FAILURE, ACUTE; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL; MALE; SYNDROME; THROMBOCYTOPENIA; VIRUS ACTIVATION;

EID: 33645709754     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20540     Document Type: Letter

References (5)

1. Westhoff TH, Jochimsen F, Schmittel A, et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003;102:1930.
2. Hernandez JA, Diloy R, Salat D, del Rio N, Martinez X, Castellvi JM. Fulminant hepatitis subsequent to reactivation of precore mutant hepatitis B virus in a patient with lymphoma treated with chemotherapy and rituximab. Haematologica 2003;88: ECR22.
3. http://www.fda.gov/medwatch/SAFETY/2004/safety04.htm#Rituxan.
4. Hamaki T, Kami M, Kusumi E, et al. Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab. Am J Hematol 2001;68:292-294.
5. Tsutsumi Y, Kawamura T, Saitoh S, et al. Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma 2004;45:627-629.